Starling Oncology Q3 EPS $(0.13) Misses $(0.05) Estimate, Sales $169.767M Beat $169.047M Estimate
Benzinga Newsdesk 2 days ago
NewsEarningsEarnings BeatsEarnings Misses
Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 7.14 percent increase over losses of $(0.14) per share from
Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 7.14 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $169.767 million which beat the analyst consensus estimate of $169.047 million by 0.43 percent. This is a 24.31 percent increase over sales of $136.564 million the same period last year.